The Argus II Retinal Prosthesis System (“Argus II”) will be initially offered in 12 major markets across the U.S. to treat patients with late stage retinitis pigmentosa (RP), according to a spokesperson for its manufacturer, Second Sight Medical Products, Inc.. This news follows U.S. market approval for the Argus II by the Food and Drug Administration (FDA) in this past February. The device is a “bionic eye.” Implant centers, based in hospitals in Ann Arbor, Atlanta, Baltimore, Chicago, Cleveland, Dallas, Durham, Los Angeles, Miami, Nashville, Philadelphia, and San Francisco--will accept consultations for patients with RP. Read more.
No comments:
Post a Comment